Calcific aortic stenosis: known facts and promising studies

Calcific aortic stenosis is a common heart disease and the most common cause of surgical interventions on heart valves in old age. Eliminated course, nonspecific clinical symptoms, and late patients seeking surgical help, lead to high mortality, reaching 50 % over the next 5 years. Despite the frequent occurrence, our knowledge of this type of aortic defect remains incomplete. About 300 years ago A. Bonnet first described defect as a random isolated pathological finding in the corpse of a Parisian tailor. Later, R. Virchow designated ectopic calcification / ossification as the main cause of the development of the disease and put forward the theory of hematogenous drift. In 1904, J. G. Mönckeberg considered calcific aortic stenosis a manifestation of “senile degeneration” of valves and blood vessels. W. S. Roberts retrospectively correlated the classic triad of symptoms with the time of death of patients with aortic stenosis. The progress of cardiac surgery in the middle of the 20^th century made it possible to describe in detail ectopic calcification as an active, progressive, recurrent and potentially modifiable process. In the works of the staff of the Nesterov’s department of facultative therapy demonstrated a high incidence of the disease in the population of the Russia. The main reason for the development of symptoms is a progressive obstruction of the exit tract of the left ventricle of the heart, its uneven hypertrophy, rhythm and conduction disturbances in combination with concomitant arterial hypertension and other comorbidities. A change in the nature of systolic murmur, underestimation of symptoms by doctors and patients themselves, the ambiguity of echocardiography data lead to late diagnosis of the disease and untimely surgical treatment. Disturbances of calcium and bone metabolism significantly reduce the functional status of patients, including due to an adverse effect on cardiac hemodynamics. Modern molecular genetic studies are aimed at finding possible ways to control a systemic inflammatory reaction, suppress lipid peroxidation, inhibit calcification and modify the osteogenic potential of interstitial cells of heart valves.

cardiovascular diseases, valvular heart disease, calcific aortic stenosis, left ventricular hypertrophy, angina pectoris, syncope, shortness of breath, bone metabolism, calcium metabolism, molecular genetic studies

1. World report on aging and health. WHO 2015. Available by: https://apps.who.int./iris/bitstream/handle/10665/186463/9789244565049_rus.pdf?sequence=10. (In Russ.)

2. Medkov V.M. Demography. Tutorial. Moscow: INFRA-M, 2003. (In Russ.)

3. Thaden J.J., Nkomo V.T., EnriquezSarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis 2014;56(6):565–71. DOI: 10.1016/j.pcad.2014.02.006.

4. Benjamin E.J., Blaha M.J., Chiuve S.E. et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017;135(10):146–603. DOI: 10.1161/CIR.0000000000000485.

5. Iung B., Baron G., Butchart E.G. et al. A prospective survey of patients with valvular heart disease in Europe: The Euro heart survey on valvular heart disease. Eur Heart J 2003;24(13):1231–43. DOI: 10.1016/s0195-668x(03)00201-x.

6. Karpova N.Yu., Shostak N.A., Rashid M.A. et al. Calcined aortic stenosis. Monograph. Moscow: Media Sphera, 2011. (In Russ.)

7. Egorov I.V. Senile aortic stenosis: century of studies. Sovremennaya revmatologiya = Modern Rheumatology Journal 2007;1(1):20–5. (In Russ.)

8. Roberts W.C. The senile cardiac calcification syndrome. Am J Cardiol 1986;58(6):572–4. DOI: 10.1016/0002-9149(86)90045-7.

9. Rajamannan N.M., Evans F.J., Aikawa E. et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group. Executive summary: calcific aortic valve disease 2011 update. Circulation 2011;124(16): 1783–1. DOI: 10.1161/CIRCULATIONAHA.110.006767.

10. Eveborn G.W., Schirmer H., Heggelund G. et al. The evolving epidemiology of valvular aortic stenosis. The Tromso study. Heart 2013;99(6):396–400. DOI: 10.1136/heartjnl-2012-302265.

11. Lindman B.R., Bonow R.O., Otto C.M. Current management of calcific aortic stenosis. Circ Res 2013;113(2):223–37. DOI: 10.1161/CIRCRESAHA.111.300084.

12. Rajappan K., Rimoldi O.E., Camici P.G. Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation 2003;107(25):3170–5. DOI: 10.1161/01.CIR.0000074211.28917.31.

13. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102(4):470–9. DOI: 10.1161/01.cir.102.4.470.

14. Carabello B.A. Is it too late to operate on the patient with valvular heart disease? J Am Coll Cardiol 2004;44(2):376–83. DOI: 10.1016/j.jacc.2004.03.061.

15. Lancellotti P., Magne J., Donal E. et al. Determinants and prognostic significance of exercise pulmonary hypertension in asymptomatic severe aortic stenosis. Circulation 2012;126(7):851–9. DOI: 10.1161/CIRCULATIONAHA.111.088427.

16. Czarny M.J., Resar J.R. Diagnosis and management of valvular aortic stenosis. Clin Med Insights Cardiol 2014; 8(Suppl.1):15–24. DOI: 10.4137/CMC.S15716.

17. Khetarpal V., Mahajan N., Madhavan R. et al. Calcific aortic valve and spontaneous embolic stroke: a review of literature. J Neurol Sci 2009;287(1–2):32–5.

18. Hudzik B., Wilczek K., Gasior M. Heyde syndrome: gastrointestinal bleeding and aortic stenosis. CMAJ 2016;188(2):135–8. DOI: 10.1503/cmaj.150194.

19. Everett R.J., Clavel M.A., Pibarot P., Dweck M.R. Timing of intervention in aortic stenosis: a review of current and future strategies. Heart 2018;104(24):2067–76. DOI: 10.1136/heartjnl-2017-312304.

20. Dzemeshkevich S.L. Aortic valve defects in adults: modern pathology and indications for surgery. Atmosfera. Novosti kardiologii = Atmosphere. Cardiology News 2003;(2):2–4. (In Russ.)

21. Mursalimova A.I., Gendlin G.E., Storozhakov G.I. Features of aortic stenosis course and diagnosis. Atmosfera. Novosti kardiologii = Atmosphere. Cardiology News 2013;(1):10–3. (In Russ.)

22. Bokeria O.L., Bazarsadaeva T.S. Sudden cardiac death and defects of the mitral and aortic valves. Annaly aritmologii = Annals of Arrhythmology 2013;10(3):162–70. (In Russ.) DOI: 10.15275/annaritmol.2013.3.6.

23. Iakovlev V.V., Korolev B.E. Calcific aortic valve disease: pathogenesis, clinic, diagnosis, the possibility of treatment. Vestnik Natsional’nogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova = Bulletin of Pirogov National Medical and Surgical Center 2015;10(3):66–70. (In Russ.)

24. Rashid M.A., Yadrov M.E., Karpova N.Yu. et al. Эпидемиологические аспекты аортального стеноза в пожилом возрасте. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2008;7(6 S.1):309. (In Russ.)

25. Shostak N.A., Karpova N.Yu., Rashid M.A. et al. Calcificated degenerative aortal stenosis: clinical and instrumental parameters. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology 2006;11(5):40–4. (In Russ.) DOI: 10.15829/1560-4071-2006-5-40-44.

26. Shostak N.A., Karpova N.Yu., Rashid M.A. Aortal stenosis with calcinosis – diagnostic principles and treatment. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice 2005;(5):52–4. (In Russ.) DOI: 10.14412/1995-4484-2005–43.

27. Rashid M.A., Shostak N.A., Karpova N.Yu. et al. Calcined aortic stenosis and blood coagulation system in various clinical manifestations of the disease. Vestnik RGMU = Bulletin of RSMU 2009;(7):79–82. (In Russ.)

28. Karpova N.Yu., Rashyd M.A., Shostak N.A., Kazakova T.V. Calcific aortic stenosis and osteoporosis: general mechanisms and perspectives of pharmacological correction. Klinitsist = The Clinician 2011;5(2):86–93. (In Russ.) DOI: 10.17650/1818-8338-2011-2-86-93.

29. Rashyd M.A., Karpova N.Yu., Shostak N.A., Kazakova T.V. Calcined aortic stenosis: bone metabolism and aortic valve calcification in elderly people. Kardiologiya i serdechno-sosudistaya khirurgiya = Russian Journal of Cardiology and Cardiovascular Surgery 2008;1(3):65–9. (In Russ.)

30. Anokhin V.N., Nazarenko G.I., Andropova O.V. New prospects for noninvasive diagnosis of aortic stenosis of degenerative genesis. Klinitsist = The Clinician 2007;(2):4–8. (In Russ.)

31. Andropova O.V., Alekseeva L.A., Minushkina L.O. The risk factors of development and progression of calcined aortic stenosis. Rossiiskiy meditsinskiy zhurnal = Russian Medical Journal 2017;23(3):152–7. (In Russ.) DOI: 10.18821/0869-2106-2017-23-3-152-157.

32. Otto C.M., Lind B.K., Kitzman D.W. et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341(3):142–7. DOI: 10.1056/NEJM199907153410302.

33. Coffey S., Cox B., Williams M.J. The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis. J Am Coll Cardiol 2014;63(25 Pt. A):2852–61. DOI: 10.1016/j.jacc.2014.04.018.

34. Nishimura R.A., Otto С.М., Bonow R.O. et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease. J Am Coll Cardiol 2014;63(22):57–185. DOI: 10.1016/j.jacc.2014.02.536.

35. Sokolov V.V., Parkhomenko M.V., Kovalyov A.I. et al. Comparative evaluation of aortic valve replacement methods in patients over 70 with aortic stenosis. Zhurnal im. N.V. Sklifosovskogo “Neotlozhnaya meditsinskaya pomoshch’” = Russian Sklifosovsky Journal “Emergency Medical Care” 2018;7(3):227–33. (In Russ.) DOI: 10.23934/2223-9022-2018-7-3-227-233.

36. Amzaev S.A., Sergeev A.S., Sukhov V.K. et al. Possibilities of interventional correction of critical aortic stenosis: contemporary state of problem and perspectives. Kreativnaya khirurgiya i onkologiya = Creative surgery and oncology 2017;7(1):4–10. (In Russ.) DOI: 10.24060/2076-3093-2017-7-1-4-10.

37. Hulin A., Hego A., Lancellotti P., Oury C. Advances in pathophysiology of calcific aortic valve disease propose novel molecular therapeutic targets (mini review). Frontiers in cardiovascular medicine 2018;5(21):1–8. DOI: 10.3389/fcvm.2018.00021.

38. Karatasakis A., Danek B.A., Karacsonyi J. et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc 2017;6(12):006910. DOI: 10.1161/JAHA.117.006910.

39. Cowell S.J., Newby D.E., Prescott R.J. et al. A randomized trial of intensive lipidlowering therapy in calcific aortic stenosis (SALTIRE). N Engl J Med 2005;352(23):2389–97. DOI: 10.1056/NEJMoa043876.

40. Rossebo A.B., Pedersen T.R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (SEAS study). N Engl J Med 2008;359(13):1343–56. DOI: 10.1056/NEJMoa0804602.

41. Chan K.L., Teo K., Dumesnil J.G. et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER trial). Circulation 2010;121(2):306–14. DOI: 10.1161/CIRCULATIONAHA.109.900027.

42. Vassiliou V.S., Flynn P.D., Raphael C.E. et al. Lipoprotein(a) in patients with aortic stenosis: insights from cardiovascular magnetic resonance. PLoS One 2017;12(7):0181077. DOI: 10.1371/journal.pone.0181077.

43. Thanassoulis G., Campbell C.Y., Owens D.S. et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368(6):503–12. DOI: 10.1056/NEJMoa1109034.

44. Lp(a) and aortic valve calcification trial (FHLPA). Available by: https://clinicaltrials.gov/ct2/show/NCT02976818.

45. Early aortic lipoprotein(a) lowering trial (EAVaLL). Available by: https://clinicaltrials.gov/ct2/show/NCT02109614.

46. Dweck M.R., Jones C., Joshi N.V. et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012;125(1):76–86. DOI: 10.1161/CIRCULATIONAHA.111.051052.

47. Pawade T.A., Cartlidge T.R., Jenkins W.S. et al. Optimization and reproducibility of aortic valve18 F-fluoride positron emission tomography in patients with aortic stenosis. Circ Cardiovasc Imaging 2016;9(10):005131. DOI: 10.1161/CIRCIMAGING.116.005131.

48. Mas-Peiro S., Hoffmann J., F lscherer S. et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J 2020;41(8): 933–9. DOI: 10.1093/eurheartj/ehz591.

49. Miller J.D., Chu Y., Brooks R.M. et al. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008;52(10):843–50. DOI: 10.1016/j.jacc.2008.05.043.

50. Choi B., Lee S., Kim S.M. et al. Dipeptidyl peptidase-4 induces aortic valve calcifcation by inhibiting insulin-like growth factor-1signaling in valvular interstitial cells. Circulation 2017;135(20):1935–50. DOI: 10.1161/CIRCULATIONAHA.116.02427075.

51. Acharya A., Hans C.P., Koenig S.N. et al. Inhibitory role of Notch1 in calcific aortic valve disease. PLoS One 2011;6(11):27743. DOI: 10.1371/journal.pone.0027743.

52. Wirrig E.E., Gomez M.V., Hinton R.B., Yutzey K.E. COX2 inhibition reduces aortic valve calcification in vivo. Arterioscler Thromb Vasc Biol 2015;35(4):938–47. DOI: 10.1161/ATVBAHA.114.305159.

53. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov 2014;13(7):513–32. DOI: 10.1038/nrd4233.

54. Aksoy O., Cam A., Goel S.S. et al. Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol 2012;59(16):1452–9. DOI: 10.1016/j.jacc.2012.01.024.

55. Innasimuthu A.L., Katz W.E. Effect of bisphosphonates on the progression of degenerative aortic stenosis. Echocardiography 2011;28(1):1–7. DOI: 10.1111/j.1540-8175.2010.01256.x.

56. Study investigating the effect of drugs used to treat osteoporosis on the progression of calcific aortic stenosis (SALTIRE II and RANKL Inhibition in Aortic Stenosis). Available by: https://clinicaltrials.gov/ct2/show/study/NCT02132026.